Inolimomab

Inolimomab is an anti-interleukin-2 receptor (IL-2R) α chain monoclonal antibody. Inolimomab improves the survival rate in the early research of treating acute graft-versus-host disease (aGVHD) [1][2].

Product Specifications

CAS Number

[152981-31-2]

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/inolimomab.html

Purity

98.78

Solubility

10 mM in DMSO

Smiles

[Inolimomab]

Molecular Weight

(145.34 kDa)

References & Citations

[1] Socié G, et al. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood. 2017 Feb 2;129 (5) :643-649. |[2]Piñana JL, et al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006 Nov;12 (11) :1135-41.